CMTM6 silencing in mesenchymal breast cancer cells partially decreased PD-L1 expression on their cell surface, while dual targeting of CMTM6 and CMTM7 significantly decreased PD-L1 in these cells. Here, CMTM6 is linked to breast cancer.